RJFSA
BIIB icon

Raymond James Financial Services Advisors’s Biogen BIIB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.59M Sell
13,382
-1,742
-12% -$364K ﹤0.01% 1590
2024
Q2 		$3.51M Buy
15,124
+226
+2% +$49.1K 0.01% 1352
2024
Q1 		$3.21M Buy
14,898
+80
+0.5% +$18.7K ﹤0.01% 1384
2023
Q4 		$3.83M Sell
14,818
-1,178
-7% -$289K 0.01% 1225
2023
Q3 		$4.11M Sell
15,996
-166
-1% -$44.4K 0.01% 1111
2023
Q2 		$4.6M Sell
16,162
-14,691
-48% -$4.37M 0.01% 1056
2023
Q1 		$8.58M Buy
30,853
+14,416
+88% +$3.99M 0.02% 757
2022
Q4 		$4.55M Sell
16,437
-4,171
-20% -$1.18M 0.01% 1004
2022
Q3 		$5.5M Sell
20,608
-882
-4% -$187K 0.01% 872
2022
Q2 		$4.38M Sell
21,490
-1,487
-6% -$304K 0.01% 984
2022
Q1 		$4.84M Sell
22,977
-6,528
-22% -$1.42M 0.01% 1018
2021
Q4 		$7.08M Buy
29,505
+13,913
+89% +$3.58M 0.01% 834
2021
Q3 		$4.41M Buy
15,592
+168
+1% +$55.1K 0.01% 1044
2021
Q2 		$5.34M Sell
15,424
-4,175
-21% -$1.26M 0.01% 948
2021
Q1 		$5.48M Sell
19,599
-1,818
-8% -$490K 0.01% 862
2020
Q4 		$5.24M Buy
21,417
+468
+2% +$121K 0.01% 816
2020
Q3 		$5.94M Sell
20,949
-7,522
-26% -$2.1M 0.02% 689
2020
Q2 		$7.62M Buy
28,471
+10,391
+57% +$3.12M 0.02% 556
2020
Q1 		$5.72M Buy
18,080
+3,645
+25% +$1.11M 0.02% 507
2019
Q4 		$4.28M Sell
14,435
-1,968
-12% -$546K 0.01% 788
2019
Q3 		$3.82M Sell
16,403
-5,210
-24% -$1.21M 0.01% 793
2019
Q2 		$5.05M Sell
21,613
-11,980
-36% -$2.77M 0.02% 674
2019
Q1 		$7.94M Buy
33,593
+6,950
+26% +$2.19M 0.03% 495
2018
Q4 		$8.02M Buy
26,643
+843
+3% +$269K 0.04% 404
2018
Q3 		$9.12M Buy
25,800
+5,313
+26% +$1.83M 0.04% 447
2018
Q2 		$5.95M Buy
20,487
+420
+2% +$118K 0.03% 535
2018
Q1 		$5.5M Sell
20,067
-1,147
-5% -$356K 0.03% 510
2017
Q4 		$6.76M Sell
21,214
-2,064
-9% -$662K 0.04% 434
2017
Q3 		$7.29M Sell
23,278
-4,566
-16% -$1.35M 0.05% 419
2017
Q2 		$7.56M Sell
27,844
-6,654
-19% -$1.76M 0.05% 397
2017
Q1 		$9.43M Buy
34,498
+5,200
+18% +$1.47M 0.07% 313
2016
Q4 		$8.31M Buy
29,298
+185
+0.6% +$54.8K 0.07% 303
2016
Q3 		$9.11M Buy
29,113
+652
+2% +$193K 0.08% 278
2016
Q2 		$6.88M Buy
28,461
+7,350
+35% +$1.94M 0.07% 317
2016
Q1 		$5.5M Buy
21,111
+3,137
+17% +$829K 0.06% 334
2015
Q4 		$5.51M Buy
+17,974
New +$5.16M 0.06% 338

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James Financial Services Advisors's BIIB Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Biogen (BIIB) stake by 12% in Q3 2024, selling an estimated $364K and leaving 13,382 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Raymond James Financial Services Advisors first reported a position in BIIB in Q4 2015 and has held it in 36 quarters since. The position peaked at $9.43M in Q1 2017. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Raymond James Financial Services Advisors held 13,382 shares of Biogen worth $2.59M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 1,742 Biogen shares in Q3 2024, an estimated $364K.
  • Biogen made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1590 holding.
  • Raymond James Financial Services Advisors first reported a position in Biogen in Q4 2015 and has held it in 36 quarters since.
  • Raymond James Financial Services Advisors's Biogen position peaked at $9.43M in Q1 2017.
  • 917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.